Inventor · disambiguated record
Jonathan Daniel Oliner
Also filed as: OLINER JONATHAN · OLINER JONATHAN D · OLINER JONATHAN DANIEL
21 granted patents·21 pending applications·600 citations·filing 1998–2025
96Inventor score
Top patents by PatentIndex Score
42 records- 0198US7138370B2Specific binding agents of human angiopoietin-2AMGEN INC·Filed 2002·Granted Nov 21, 2006·100 cites·25 claims
- 0295US7658924B2Angiopoietin-2 specific binding agentsAMGEN INC·Filed 2004·Granted Feb 9, 2010·73 cites·9 claims
- 0395US7521053B2Angiopoietin-2 specific binding agentsAMGEN INC·Filed 2002·Granted Apr 21, 2009·89 cites·17 claims
- 0494US8030025B2Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereofAMGEN INC·Filed 2009·Granted Oct 4, 2011·21 cites·28 claims
- 0594US7723499B2Specific binding agents of human angiopoietin-2AMGEN INC·Filed 2006·Granted May 25, 2010·18 cites·24 claims
- 0693US7205275B2Methods of treatment using specific binding agents of human angiopoietin-2AMGEN INC·Filed 2003·Granted Apr 17, 2007·41 cites·5 claims
- 0792US7666832B2Methods of treatment using specific binding agents of human angiopoietin-2AMGEN INC·Filed 2006·Granted Feb 23, 2010·16 cites·9 claims
- 0892US7666839B2Methods of treatment using specific binding agents of human angiopoietin-2AMGEN INC·Filed 2006·Granted Feb 23, 2010·16 cites·13 claims
- 0991US7790674B2Methods of treatment using specific binding agents of human angiopoietin-2AMGEN INC·Filed 2006·Granted Sep 7, 2010·12 cites·15 claims
- 1090US12313624B2Ex vivo systems and methods for determining the effect of a drug or other agent on a tissueELEPHAS BIOSCIENCES CORP·Filed 2022·Granted May 27, 2025·4 cites·16 claims
- 1189US11366101B1Ex vivo systems and methods for determining the effect of a drug or other agent on a tissueELEPHAS BIOSCIENCES CORP·Filed 2021·Granted Jun 21, 2022·3 cites·23 claims
- 1289US6746844B2Determining signal transduction pathwaysAFFYMETRIX INC·Filed 2002·Granted Jun 8, 2004·17 cites·33 claims
- 1387US7666831B2Methods of treatment using specific binding agents of human angiopoietin-2AMGEN INC·Filed 2006·Granted Feb 23, 2010·7 cites·11 claims
- 1484US8221749B2Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereofBOONE THOMAS C·Filed 2011·Granted Jul 17, 2012·5 cites·13 claims
- 1583US6177248B1Downstream genes of tumor suppressor WT1AFFYMETRIX INC·Filed 1999·Granted Jan 23, 2001·103 cites·26 claims
- 1681US8129331B2Specific binding agents of human angiopoietin-2OLINER JONATHAN DANIEL·Filed 2007·Granted Mar 6, 2012·3 cites·4 claims
- 1780US10881648B2Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancersAMGEN INC·Filed 2018·Granted Jan 5, 2021·1 cites·20 claims
- 1878US6340565B1Determining signal transduction pathwaysAFFYMETRIX INC·Filed 1999·Granted Jan 22, 2002·32 cites·33 claims
- 1973US2025264454A1Ex vivo systems and methods for determining the effect of a drug or other agent on a tissueELEPHAS BIOSCIENCES CORP·Filed 2025·Application pending·0 cites
- 2072US9200040B2Specific binding agents of human angiopoietin-2OLINER JONATHAN DANIEL·Filed 2012·Granted Dec 1, 2015·1 cites·17 claims
- 2170US6258536B1Expression monitoring of downstream genes in the BRCA1 pathwayFiled 1998·Granted Jul 10, 2001·38 cites·32 claims
- 2265US2009191212A1Angiopoietin-2 Specific Binding AgentsAMGEN INC·Filed 2009·Application pending·0 cites
- 2365US2022280495A1Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of CancersAMGEN INC·Filed 2021·Application pending·0 cites
- 2463US2005019797A1Determining signal transduction pathwaysAFFYMETRIX INC·Filed 2004·Application pending·0 cites
- 2563US2014275479A1Specific binding agents of human angiopoeitin-2OLINER JONATHAN DANIEL·Filed 2014·Application pending·0 cites
- 2661US2013336992A1Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereofAMGEN INC·Filed 2013·Application pending·0 cites
- 2760US10336820B2Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereofAMGEN INC·Filed 2016·Granted Jul 2, 2019·0 cites·17 claims
- 2860US2024302253A1Systems and methods for tissue cutting system with visionELEPHAS BIOSCIENCES CORP·Filed 2024·Application pending·0 cites
- 2959US2012258122A1Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 and Uses ThereofBOONE THOMAS C·Filed 2012·Application pending·0 cites
- 3058US2013158234A1Specific binding agents of human angiopoietin-2OLINER JONATHAN DANIEL·Filed 2012·Application pending·0 cites
- 3157US2023296589A1Antibody fragments and uses thereof for imaging cellular activityELEPHAS BIOSCIENCES CORP·Filed 2023·Application pending·0 cites
- 3257US2013142799A1Angiopoietin-2 Specific Binding AgentsAMGEN INC·Filed 2012·Application pending·0 cites
- 3356US2010286060A1Specific binding agents of human angiopoeitin-2AMGEN INC·Filed 2010·Application pending·0 cites
- 3455US2021405056A1Methods for detecting mutant p53 functionPMV PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3555US2009053763A1Tumor endothelial marker 7-alpha molecules and uses thereofAMGEN INC·Filed 2008·Application pending·0 cites
- 3654US2016287569A1Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancersAMGEN INC·Filed 2014·Application pending·0 cites
- 3753US2023081048A1Tissue cutting system and methodELEPHAS BIOSCIENCES CORP·Filed 2022·Application pending·0 cites
- 3852US2011311546A1Angiopoietin-2 specific binding agentsOLINER JONATHAN DANIEL·Filed 2011·Application pending·0 cites
- 3952US2001051339A1Expression monitoring of downstream genes in the BRCA1 pathwayFiled 2001·Application pending·0 cites
- 4046US2009304694A1Ang2 and Vegf Inhibitor CombinationsAMGEN INC·Filed 2007·Application pending·0 cites
- 4145US2003092025A1Tumore endothelial market 7alpha molecules and uses thereofAMGEN INC A CORP OF THE STATE·Filed 2002·Application pending·0 cites
- 4236US2017233467A1Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular TherapiesAMGEN INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan Daniel Oliner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →